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Objective: To assess risk factors favoring 
VTE over ASCVD in patients with 
rheumatoid arthritis (RA).
Methods: RA patients participating in 
FORWARD from 1998 through 2018 
were assessed for incident nonfatal/fatal 
unprovoked VTE (no active cancer, recent 
surgery, hospitalization, fracture, pregnancy) 
and ASCVD (myocardial infarction and 
stroke) validated from hospital/death records. 
Patients with prior VTE/ASCVD and active 
cancer were excluded. The risk factors for 
VTE and ASCVD were determined separately 
using Cox proportional hazards compared 





ASCVD events during median (IQR) four 
(1.5-7) years of follow-up. The incidence 
rates per 10,000 patient-years (95% CI) 
were 0.34 (0.31-0.37) for VTE and 1.57 
(1.51-1.63) for ASCVD. The multivariable 
models showed that older age, being male, 
having more comorbidities, prior fractures, 
disability, moderate/high disease activity and 
glucocorticoids were associated with both 
increased VTE and ASCVD risks (Table 1).  
Traditional CV risk factors, DM and HT 
increased only ASCVD risk. Obesity had 







Conclusion: With different risk magnitudes, 
VTE and ASCVD share common risk 
factors representing RA disease severity 
including disability, high disease activity 
and glucocorticoid use. The main difference 
in risk factors for these CV events is the 
traditional CV risk factors; DM and HT 
increase ASCVD risk and obesity increases 




Multivariable associations with VTE and ASCVD in patients with RA*
Variables 
	!	"#		
VTE vs. no CVD 

	!	"#		
ASCVD vs. no CVD 
Age Groups
<45 years Reference Reference
45-64 years 1.58 (1.02-2.43) 3.01 (1.87-4.86)
	 2.30 (1.43-3.69) 7.85 (4.82-12.80)
Male 1.36 (1.06-1.73) 1.76 (1.53-2.03)
Caucasian 0.94 (0.66-1.34) 1.20 (0.96-1.46)
RA duration, years 1.00 (0.99-1.01) 1.00 (0.99-1.00)
BMI in WHO categories
Underweight 0.64 (0.26-1.58) 1.51 (1.13-2.02)
Normal weight Reference Reference
Overweight 1.03 (0.80-1.33) 0.74 (0.64-0.84)
Obese 1.46 (1.13-1.87) 0.58 (0.50-0.68)
Exercise 1.04 (0.92-1.17) 1.19 (1.00-1.20)
RDCI 1.21 (1.14-1.30) 1.12 (1.07-1.17)
Ever-smoked 0.90 (0.74-1.08) 1.05 (0.94-1.18)
Diabetes 0.97 (0.75-1.25) 1.35 (1.15-1.59)
Hypertension 1.18 (0.8-1.43) 1.20 (1.06-1.35)
Pulmonary disease 0.94 (0.71-1.26) 0.98 (0.81-1.19)
Prior fracture 1.59 (1.37-1.84) 1.17 (1.04-1.33)
Prior cancer 1.12 (0.86-1.45) 1.07 (0.90-1.26)
HAQ disability (0-3) 1.21 (1.03-1.42) 1.28 (1.16-1.42)
Moderate/high disease activity vs. 
Remission/low disease activity¶
1.29 (1.05-1.57) 1.30 (1.16-1.47)
Medication use
Glucocorticoids 1.98 (1.64-2.38) 1.36 (1.21-1.52)
MTX 1.02 (0.85-1.22) 0.91 (0.81-1.02)
Hydroxychloroquine 0.80 (0.63-0.99) 0.80 (0.69-0.93)
TNFi 1.08 (0.88-1.33) 1.01 (0.87-1.16)
Other b/tsDMARD 0.86 (0.63-1.17) 1.09 (0.80-1.48)
NSAID 0.76(0.62-1.00) 0.94 (0.89-1.01)
Aspirin 0.80 (0.64-1.01) 1.10 (0.99-1.32)
Statin 1.02 (0.82-1.27) 1.11 (0.96-1.29)
Estrogen 0.93 (0.70-1.25) 0.88 (0.7-1.04)
* The model also included location of residence, insurance type, annual income, and calendar year. 
¶ Disease activity assessed by PAS (evaluated in a separate model without individual components of PAS)
